Syndecan peptides and polypeptides as inhibitors of cancer
The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit α4β6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion.
1. A peptide consisting of:
(a) a peptide segment consisting of between 30 and 100 amino acid residues and comprising residues 210-235 of SEQ ID NO:1, wherein one or more of the between 30 and 100 amino acids are D-amino acids; or
(b) a peptide segment consisting of between 30 and 100 amino acid residues and comprising residues 210-235 of SEQ ID NO:1, and a blocking agent that is attached to the amino terminal and/or carboxyl terminal residues of the peptide segment.
2. The peptide of claim 1 , wherein said peptide segment is 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 70, 75, 80, 85, 90, 95 or 100 amino acid residues in length.
3. The peptide of claim 1 , wherein said peptide segment is between 31 and 80 amino acid residues in length.
4. The peptide of claim 1 , wherein said peptide segment is between 61 and 80 amino acid residues in length.
5. The peptide of claim 1 , wherein said peptide segment is between 66 and 80 amino acid residues in length.
6. The peptide of claim 1 , wherein said peptide segment comprises residues 210-240 of SEQ ID NO:1 (SEQ ID NO:3).
7. The peptide of claim 1 , wherein said peptide segment consists of residues 210-235 of SEQ ID NO:1 (SEQ ID NO:2) or residues 210-240 of SEQ ID NO:1 (SEQ ID NO:3).
8. The peptide of claim 1 , wherein said peptide segment consists essentially of residues 210-240 of SEQ ID NO:1 (SEQ ID NO:3), 210-249 of SEQ ID NO:1 (SEQ ID NO: 4), 175-235 of SEQ ID NO:1 (SEQ ID NO:5) or 175-240 of SEQ ID NO:1 (SEQ ID NO:6).
9. The peptide of claim 1 , wherein said peptide segment consists of residues 210-240 of SEQ ID NO:1 (SEQ ID NO: 3), 210-249 of SEQ ID NO:1 (SEQ ID NO: 4), 175-235 of SEQ ID NO:1 (SEQ ID NO: 5) or 175-240 of SEQ ID NO:1 (SEQ ID NO: 6).
10. The peptide of claim 1 , wherein said peptide segment is between 31 and 61 amino acid residues in length.
11. A method of inhibiting scarring in a subject comprising administering to said subject the peptide of claim 1 , whereby scarring is inhibited in the subject.
12. A method of inhibiting pathologic neovascularization in a subject comprising administering to said subject the peptide of claim 1 , whereby pathological neovascularization is inhibited in the subject.
13. The method of claim 12 , wherein said peptide segment is 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 70, 75, 80, 85, 90, 95 or 100 amino acid residues in length.
14. The method of claim 12 , wherein said peptide segment is between 31 and 80 amino acid residues in length.
15. The method of claim 12 , wherein said peptide segment is between 61 and 80 amino acid residues in length.
16. The method of claim 12 , wherein said peptide segment is between 66 and 80 amino acid residues in length.
17. The method of claim 12 , wherein said peptide segment consists essentially of residues 210-235 of SEQ ID NO:1 (SEQ ID NO: 2) or residues 210-240 of SEQ ID NO:1 (SEQ ID NO:3).
18. The method of claim 12 , wherein said peptide segment comprises residues 210-240 of SEQ ID NO:1 (SEQ ID NO:3).
19. The method of claim 12 , wherein said peptide segment consists essentially of residues 210-240 of SEQ ID NO:1 (SEQ ID NO: 3), 210-249 of SEQ ID NO:1 (SEQ ID NO: 4), 175-235 of SEQ ID NO:1 (SEQ ID NO: 5) or 175-240 of SEQ ID NO:1 (SEQ ID NO: 6).
20. The method of claim 12 , wherein said peptide segment consists of residues 210-240 of SEQ ID NO:1 (SEQ ID NO:3), 210-249 of SEQ ID NO:1 (SEQ ID NO:4), 175-235 of SEQ ID NO:1 (SEQ ID NO:5) or 175-240 of SEQ ID NO:1 (SEQ ID NO:6).
21. The method of claim 12 , wherein said pathological neovascularization involves activated vascular endothelial cells.